Acquisition du Centre d'oncologie de la Porte de Saint-Cloud

Stingray Healthcare Group, through its French operations Amethyst, announces the acquisition of the Porte de Saint-Cloud Oncology Centre as part of a strategic partnership with the American Hospital of Paris.

Paris, le 10 juin 2026 – Stingray Healthcare Group (“Stingray”), through its French operations Amethyst, today announces the acquisition of the Porte de Saint-Cloud Oncology Centre (“CCPSC”), previously owned by the American Hospital of Paris (“AHP”).

This partnership is designed to strengthen access to radiotherapy services for patients across the Île-de-France region, where Stingray already operates two centres in La Garenne-Colombes and Versailles.

Through this partnership, Stingray and the AHP aim to provide patients with rapid access to state-of-the-art oncology treatments, while ensuring continuity and quality of care.

Built on the complementary expertise of Stingray and the AHP, the partnership seeks to further enhance the patient experience and strengthen oncology care delivery within a highly demanding clinical environment.

The CCPSC, which will operate under the Amethyst brand, will continue to rely on its existing teams and established clinical standards, ensuring a seamless transition for patients and healthcare professionals.

Déclarations

Olivier Cosset, CEO Amethyst Radiotherapie France and COO, Stingray Healthcare Group
“This milestone marks an important step in the development of Stingray and Amethyst in the Île-de-France region, alongside our centres in La Garenne-Colombes and Versailles. Our priority is to broaden patient access to innovative cancer treatments within a coordinated care pathway that upholds the highest standards of quality, in close collaboration with the teams at the American Hospital of Paris.”

Benoît Gallix, Chief Executive Officer, American Hospital of Paris
“This partnership with Stingray and Amethyst reflects our commitment to the continuity and further development of a medical programme of excellence, dedicated to providing patients with high-quality care at every stage of their treatment journey. It will strengthen oncology care provision while drawing on the expertise of a trusted partner in the field of radiotherapy.”

À propos de Stingray Healthcare Group

Stingray Healthcare Group is Europe’s largest network of specialised oncology centres, operating 33 centres across eight countries, including 12 in France, and providing radiotherapy treatment to more than 35,000 patients each year.The Group’s medical teams offer the full range of standard outpatient cancer treatments, together with numerous related medical specialties, delivering high-quality, patient-centred care across all of its centres.

Presse contact

Sophie Ward: [email protected]

Karen Bornaghi: [email protected]

Christian d’Oléon: [email protected]